Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.» Read More
Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.
European equities closed mixed on Monday as investors reacted to new economic data and cheered updates from the pharmaceutical sector.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.
European shares finished mixed on Wednesday, as investors digested a slew of earnings from European companies.
Roche, the world's biggest maker of cancer drugs, reported a 3 percent rise in sales in the first quarter on Wednesday.
Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
“Mad Money” host Jim Cramer on why this rally won’t last forever and why you should take some off the table on this.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.
Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.
Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.
European markets ended mixed on Wednesday after seesawing for much of the session, with indexes pressures by a staggering slump in Greek bank stocks.
Here are the fund managers Morningstar considers the best of the best.
The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.